These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 24343157)

  • 21. [Long-term application of the multiple sclerosis functional composite test in Debrecen, Hungary].
    Mezei Z; Bereczki D; Csiba L; Csépány T
    Ideggyogy Sz; 2006 Nov; 59(11-12):442-7. PubMed ID: 17203882
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multimodal evoked potentials measure and predict disability progression in early relapsing-remitting multiple sclerosis.
    Jung P; Beyerle A; Ziemann U
    Mult Scler; 2008 May; 14(4):553-6. PubMed ID: 18562509
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Course of relapsing-remitting multiple sclerosis before, during and after natalizumab.
    Kaufman MD; Lee R; Norton HJ
    Mult Scler; 2011 Apr; 17(4):490-4. PubMed ID: 21135017
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A patient with established primary progressive multiple sclerosis transitions to 'secondary' relapsing-remitting disease course following a fulminant demyelinating episode.
    Tutuncu M; Demirci NO; Özer F; Saip S; Kantarci OH; Siva A
    Mult Scler; 2011 Oct; 17(10):1262-4. PubMed ID: 21135019
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Multiple sclerosis: spontaneous course, natural history].
    Vukusic S; Moreau T; Bouhour F; Adeleine P; Confavreux C
    Rev Neurol (Paris); 2001 Sep; 157(8-9 Pt 1):753-6. PubMed ID: 11677394
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Brain atrophy in relapsing-remitting multiple sclerosis and secondary progressive multiple sclerosis: longitudinal quantitative analysis.
    Ge Y; Grossman RI; Udupa JK; Wei L; Mannon LJ; Polansky M; Kolson DL
    Radiology; 2000 Mar; 214(3):665-70. PubMed ID: 10715027
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Natalizumab strongly suppresses cortical pathology in relapsing-remitting multiple sclerosis.
    Rinaldi F; Calabrese M; Seppi D; Puthenparampil M; Perini P; Gallo P
    Mult Scler; 2012 Dec; 18(12):1760-7. PubMed ID: 22570359
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial.
    Togha M; Karvigh SA; Nabavi M; Moghadam NB; Harirchian MH; Sahraian MA; Enzevaei A; Nourian A; Ghanaati H; Firouznia K; Jannati A; Shekiba M
    Mult Scler; 2010 Jul; 16(7):848-54. PubMed ID: 20488825
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of mothball powder composition by float tests and melting point tests.
    Tang KY
    Clin Toxicol (Phila); 2018 Jul; 56(7):626-632. PubMed ID: 29172744
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Determinants of disability in multiple sclerosis at various disease stages: a multiparametric magnetic resonance study.
    Pulizzi A; Rovaris M; Judica E; Sormani MP; Martinelli V; Comi G; Filippi M
    Arch Neurol; 2007 Aug; 64(8):1163-8. PubMed ID: 17698707
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A representative cohort of patients with non-progressive multiple sclerosis at the age of normal life expectancy.
    Skoog B; Runmarker B; Winblad S; Ekholm S; Andersen O
    Brain; 2012 Mar; 135(Pt 3):900-11. PubMed ID: 22366800
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative effectiveness of early natalizumab treatment in JC virus-negative relapsing-remitting multiple sclerosis.
    Campbell JD; McQueen RB; Miravalle A; Corboy JR; Vollmer TL; Nair K
    Am J Manag Care; 2013 Apr; 19(4):278-85. PubMed ID: 23725360
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cognitive reserve and symptom experience in multiple sclerosis: a buffer to disability progression over time?
    Schwartz CE; Quaranto BR; Healy BC; Benedict RH; Vollmer TL
    Arch Phys Med Rehabil; 2013 Oct; 94(10):1971-81. PubMed ID: 23727344
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Primary progressive versus relapsing-onset multiple sclerosis: presence and prognostic value of cerebrospinal fluid oligoclonal IgM.
    Sola P; Mandrioli J; Simone AM; Ferraro D; Bedin R; Annecca R; Venneri MG; Nichelli PF; Merelli E
    Mult Scler; 2011 Mar; 17(3):303-11. PubMed ID: 21078694
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing-remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study.
    Patti F; Amato MP; Trojano M; Bastianello S; Tola MR; Goretti B; Caniatti L; Di Monte E; Ferrazza P; Brescia Morra V; Lo Fermo S; Picconi O; Luccichenti G;
    Mult Scler; 2009 Jul; 15(7):779-88. PubMed ID: 19542262
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cortical lesion load associates with progression of disability in multiple sclerosis.
    Calabrese M; Poretto V; Favaretto A; Alessio S; Bernardi V; Romualdi C; Rinaldi F; Perini P; Gallo P
    Brain; 2012 Oct; 135(Pt 10):2952-61. PubMed ID: 23065788
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The transition from relapsing-remitting MS to irreversible disability: clinical evaluation.
    Trojano M; Paolicelli D; Bellacosa A; Cataldo S
    Neurol Sci; 2003 Dec; 24 Suppl 5():S268-70. PubMed ID: 14652786
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS.
    Kappos L; Traboulsee A; Constantinescu C; Erälinna JP; Forrestal F; Jongen P; Pollard J; Sandberg-Wollheim M; Sindic C; Stubinski B; Uitdehaag B; Li D
    Neurology; 2006 Sep; 67(6):944-53. PubMed ID: 17000959
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Natalizumab vs interferon beta 1a in relapsing-remitting multiple sclerosis: a head-to-head retrospective study.
    Lanzillo R; Quarantelli M; Bonavita S; Ventrella G; Lus G; Vacca G; Prinster A; Orefice G; Tedeschi G; Brescia Morra V
    Acta Neurol Scand; 2012 Nov; 126(5):306-14. PubMed ID: 22107083
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Increased plasma 8,12-iso-iPF2alpha- VI levels in relapsing multiple sclerosis patients are not predictive of disease progression.
    Teunissen CE; Sombekke M; van Winsen L; Killestein J; Barkhof F; Polman CH; Dijkstra CD; Blankenstein MA; Pratico D
    Mult Scler; 2012 Aug; 18(8):1092-8. PubMed ID: 22695538
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.